GLP-1 agonists, such as ROSE-010, relieve pain in IBS patients by altering gut motility (43), lowering inflammation (44), modulating neurotransmitters (45), reducing visceral hypersensitivity (46), and interacting with the gut microbiota (47). This evidence concerns the gene GCG and irritable bowel syndrome.